Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (OBERON)

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (OBERON)

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease (COPD)
• Intervention / Treatment: Drug: Tozorakimab; Drug: Tozorakimab; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 1132
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1121 ABE
    • Research Site
  • CABA, Argentina, C1425BEN
    • Research Site
  • Ciudad de Buenos Aires, Argentina, C1414AIF
    • Research Site
  • Córdoba, Argentina, X5003DCE
    • Research Site
  • Mar del Plata, Argentina, 7600
    • Research Site
  • Mar del Plata, Argentina, B7600GWV
    • Research Site
  • Mendoza, Argentina, M5500CCG
    • Research Site
  • Quilmes, Argentina, B1878FNR
    • Research Site
  • San Fernando, Argentina, B1646EBJ
    • Research Site
  • San Juan Bautista, Argentina, 1888
    • Research Site
  • San Miguel de Tucumán, Argentina, 4000
    • Research Site
• Belgium
  • Brussels, Belgium, 1000
    • Research Site
  • Ghent, Belgium, 9000
    • Research Site
  • Leuven, Belgium, 3000
    • Research Site
  • Liège, Belgium, 4000
    • Research Site
  • Namur, Belgium, 5101
    • Research Site
• Bulgaria
  • Dupnitsa, Bulgaria, 2600
    • Research Site
  • Haskovo, Bulgaria, 6305
    • Research Site
  • Kozloduy, Bulgaria, 3320
    • Research Site
  • Lovech, Bulgaria, 5500
    • Research Site
  • Petrich, Bulgaria, 2850
    • Research Site
  • Pleven, Bulgaria, 5800
    • Research Site
  • Rousse, Bulgaria, 7002
    • Research Site
  • Sliven, Bulgaria, 8800
    • Research Site
  • Sofia, Bulgaria, 1000
    • Research Site
  • Sofia, Bulgaria, 1606
    • Research Site
  • Troyan Municipality, Bulgaria, 5600
    • Research Site
  • Vratsa, Bulgaria, 3000
    • Research Site
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T3E 7M8
      • Research Site
    • Edmonton, Alberta, Canada, T5A 4L8
      • Research Site
    • Sherwood Park, Alberta, Canada, T8L 0N2
      • Research Site
  • British Columbia
    • Kamloops, British Columbia, Canada, V2C 5T1
      • Research Site
    • Kelowna, British Columbia, Canada, V1Y 4N7
      • Research Site
  • Ontario
    • Ajax, Ontario, Canada, L1S 2J5
      • Research Site
    • Guelph, Ontario, Canada, N1H 6J2
      • Research Site
    • Markham, Ontario, Canada, L3T 0C8
      • Research Site
    • Stouffville, Ontario, Canada, L4A 1H2
      • Research Site
    • Winchester, Ontario, Canada, K0C 2K0
      • Research Site
  • PQ
    • Montreal, PQ, Canada, H3T 1E2
      • Research Site
  • Quebec
    • Québec, Quebec, Canada, G1V 4G5
      • Research Site
    • Québec, Quebec, Canada, G1G 5X1
      • Research Site
    • Terrebonne, Quebec, Canada, J6V 2H2
      • Research Site
• Czechia
  • Brno, Czechia, 625 00
    • Research Site
  • Broumov, Czechia, 55001
    • Research Site
  • Jindřichův Hradec, Czechia, 377 01
    • Research Site
  • Liberec, Czechia, 460 63
    • Research Site
  • Olomouc, Czechia, 779 00
    • Research Site
  • Rokycany, Czechia, 337 22
    • Research Site
• Denmark
  • Aalborg, Denmark, 9000
    • Research Site
  • Hvidovre, Denmark, 2650
    • Research Site
  • København NV, Denmark, 2400
    • Research Site
  • Næstved, Denmark, 4700
    • Research Site
  • Roskilde, Denmark, 4000
    • Research Site
  • Vejle, Denmark, 7100
    • Research Site
• Finland
  • Helsinki, Finland, 00290
    • Research Site
  • Hämeenlinna, Finland, 13530
    • Research Site
  • Kuopio, Finland, 70210
    • Research Site
  • Tampere, Finland, 33520
    • Research Site
  • Turku, Finland, 20100
    • Research Site
  • Turku, Finland, FI-20521
    • Research Site
• Hungary
  • Budapest, Hungary, 1036
    • Research Site
  • Debrecen, Hungary, 4032
    • Research Site
  • Edelény, Hungary, 3780
    • Research Site
  • Encs, Hungary, 3860
    • Research Site
  • Mosonmagyaróvár, Hungary, 9200
    • Research Site
  • Nyíregyháza-Sóstóhegy, Hungary, 4481
    • Research Site
  • Százhalombatta, Hungary, 2440
    • Research Site
• India
  • Ahmedabad, India, 382415
    • Research Site
  • Belagavi, India, 590010
    • Research Site
  • Coimbatore, India, 641028
    • Research Site
  • Dehradun, India, 248001
    • Research Site
  • Hyderabad, India, 500038
    • Research Site
  • Jaipur, India, 302039
    • Research Site
  • Mohali, India, 160062
    • Research Site
  • Nagpur, India, 440012
    • Research Site
  • Nashik, India, 422007
    • Research Site
  • New Delhi, India, 110029
    • Research Site
  • Surat, India, 395009
    • Research Site
  • Thane, India, 401107
    • Research Site
• Japan
  • Asahikawa-shi, Japan, 078-8510
    • Research Site
  • Chikushino-shi, Japan, 818-8502
    • Research Site
  • Chūōku, Japan, 103-0022
    • Research Site
  • Fujieda-shi, Japan, 426-8677
    • Research Site
  • Fukuoka, Japan, 819-8555
    • Research Site
  • Hamamatsu, Japan, 431-3192
    • Research Site
  • Hamamatsu, Japan, 430-8525
    • Research Site
  • Hiroshima, Japan, 734-8530
    • Research Site
  • Iizuka-shi, Japan, 820-8505
    • Research Site
  • Itabashi-ku, Japan, 173-8610
    • Research Site
  • Iwata-shi, Japan, 438-8550
    • Research Site
  • Joyo-shi, Japan, 610-0113
    • Research Site
  • Kagoshima, Japan, 890-8520
    • Research Site
  • Kanazawa, Japan, 920-8650
    • Research Site
  • Kawachinagano-shi, Japan, 586-8521
    • Research Site
  • Kitakyusyu-shi, Japan, 806-8501
    • Research Site
  • Kobe, Japan, 651-0072
    • Research Site
  • Koga-shi, Japan, 811-3195
    • Research Site
  • Kokubunji-shi, Japan, 185-0014
    • Research Site
  • Matsusaka-shi, Japan, 515-8544
    • Research Site
  • Mizunami-shi, Japan, 509-6134
    • Research Site
  • Nagaoka-shi, Japan, 940-8621
    • Research Site
  • Nagoya, Japan, 460-0001
    • Research Site
  • Obihiro, Japan, 080-0017
    • Research Site
  • Okayama, Japan, 700-8558
    • Research Site
  • Osaka, Japan, 545-8586
    • Research Site
  • Osaka, Japan, 543-8555
    • Research Site
  • Osaka, Japan, 531-0073
    • Research Site
  • Sakaishi, Japan, 590-0064
    • Research Site
  • Shinjuku-ku, Japan, 162-8655
    • Research Site
  • Shizuoka, Japan, 420-8630
    • Research Site
  • Toshima-ku, Japan, 170-0003
    • Research Site
  • Toyonaka-shi, Japan, 560-8552
    • Research Site
  • Yanagawa-shi, Japan, 832-0059
    • Research Site
  • Yokohama, Japan, 232-0024
    • Research Site
  • Yokohama, Japan, 223-0059
    • Research Site
  • Yokohama, Japan, 221-0855
    • Research Site
• Mexico
  • Benito Juárez, Mexico, 03650
    • Research Site
  • Chihuahua City, Mexico, 31000
    • Research Site
  • Guadalajara, Mexico, 44200
    • Research Site
  • Guadalajara, Mexico, 44100
    • Research Site
  • Mexico City, Mexico, 0 3100
    • Research Site
  • Monterrey, Mexico, 64460
    • Research Site
  • Morelia, Mexico, 58000
    • Research Site
  • Mérida, Mexico, 97070
    • Research Site
  • Oaxaca City, Mexico, 68020
    • Research Site
  • Veracruz, Mexico, 91910
    • Research Site
• Netherlands
  • Alkmaar, Netherlands, 1815 JD
    • Research Site
  • Eindhoven, Netherlands, 5623EJ
    • Research Site
  • Groningen, Netherlands, 9713 GZ
    • Research Site
  • Harderwijk, Netherlands, 3844 DG
    • Research Site
  • Heerlen, Netherlands, 6419 PC
    • Research Site
  • Zutphen, Netherlands, 7207 AE
    • Research Site
  • Zwolle, Netherlands, 8025 AB
    • Research Site
• Norway
  • Bergen, Norway, 5021
    • Research Site
  • Bodø, Norway, 8092
    • Research Site
  • Levanger, Norway, 7600
    • Research Site
  • Lørenskog, Norway, 1478
    • Research Site
  • Oslo, Norway, 0450
    • Research Site
  • Tønsberg, Norway, 3103
    • Research Site
  • Ålesund, Norway, 6017
    • Research Site
• Portugal
  • Guimarães, Portugal, 4835-235
    • Research Site
  • Lisbon, Portugal, 1998-018
    • Research Site
  • Lisbon, Portugal, 1769-001
    • Research Site
  • Matosinhos Municipality, Portugal, 4454-509
    • Research Site
  • Vila Franca de Xira, Portugal, 2600-009
    • Research Site
  • Vila Nova de Gaia, Portugal, 4434-502
    • Research Site
• Puerto Rico
  • Guaynabo, Puerto Rico, 00968
    • Research Site
• South Korea
  • Daegu, South Korea, 42415
    • Research Site
  • Incheon, South Korea, 21431
    • Research Site
  • Jeonju, South Korea, 54907
    • Research Site
  • Seoul, South Korea, 03722
    • Research Site
  • Seoul, South Korea, 05505
    • Research Site
  • Seoul, South Korea, 06591
    • Research Site
  • Seoul, South Korea, 05030
    • Research Site
  • Seoul, South Korea, 07061
    • Research Site
• Spain
  • Galdakao, Spain, 48960
    • Research Site
  • Madrid, Spain, 28040
    • Research Site
  • Málaga, Spain, 29010
    • Research Site
  • Mérida, Spain, 06800
    • Research Site
  • Pozuelo de Alarcón, Spain, 28223
    • Research Site
  • Santander, Spain, 39008
    • Research Site
  • Valencia, Spain, 46010
    • Research Site
  • Zaragoza, Spain, 50009
    • Research Site
• Sweden
  • Gothenburg, Sweden, 413 45
    • Research Site
  • Gothenburg, Sweden, 413 46
    • Research Site
  • Lund, Sweden, 222 22
    • Research Site
  • Malmo, Sweden, 205 02
    • Research Site
  • Stockholm, Sweden, 11239
    • Research Site
• Turkey (Türkiye)
  • Ankara, Turkey (Türkiye), 06620
    • Research Site
  • Aydin, Turkey (Türkiye), 09100
    • Research Site
  • Istanbul, Turkey (Türkiye), 34069
    • Research Site
  • Izmir, Turkey (Türkiye), 35965
    • Research Site
  • Izmir, Turkey (Türkiye), 35040
    • Research Site
  • Mersin, Turkey (Türkiye), 33343
    • Research Site
• United States
  • Alabama
    • Huntsville, Alabama, United States, 35801
      • Research Site
    • Mobile, Alabama, United States, 36608
      • Research Site
    • Montgomery, Alabama, United States, 36106
      • Research Site
  • Arizona
    • Phoenix, Arizona, United States, 85044
      • Research Site
  • California
    • Bakersfield, California, United States, 93301
      • Research Site
    • Sacramento, California, United States, 95821
      • Research Site
  • Florida
    • Boynton Beach, Florida, United States, 33435
      • Research Site
    • Ormond Beach, Florida, United States, 32174
      • Research Site
    • Plantation, Florida, United States, 33324
      • Research Site
  • Idaho
    • Meridian, Idaho, United States, 83642
      • Research Site
  • Illinois
    • Evergreen Park, Illinois, United States, 60805
      • Research Site
    • Normal, Illinois, United States, 61761
      • Research Site
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Research Site
  • Kansas
    • Kansas City, Kansas, United States, 66104
      • Research Site
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70816
      • Research Site
    • Zachary, Louisiana, United States, 70791
      • Research Site
  • Maryland
    • Baltimore, Maryland, United States, 21224
      • Research Site
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Research Site
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Research Site
  • Montana
    • Missoula, Montana, United States, 59808
      • Research Site
  • New Jersey
    • Brick, New Jersey, United States, 08724
      • Research Site
  • New York
    • New York, New York, United States, 10037
      • Research Site
    • The Bronx, New York, United States, 10455
      • Research Site
  • North Carolina
    • Charlotte, North Carolina, United States, 28277
      • Research Site
    • Durham, North Carolina, United States, 27710
      • Research Site
    • Gastonia, North Carolina, United States, 28054
      • Research Site
  • North Dakota
    • Fargo, North Dakota, United States, 58104
      • Research Site
  • Pennsylvania
    • DuBois, Pennsylvania, United States, 15801
      • Research Site
    • Pittsburgh, Pennsylvania, United States, 15213
      • Research Site
    • Sayre, Pennsylvania, United States, 18840
      • Research Site
  • South Dakota
    • Rapid City, South Dakota, United States, 57702
      • Research Site
  • Tennessee
    • Franklin, Tennessee, United States, 37067
      • Research Site
  • Texas
    • Houston, Texas, United States, 77022
      • Research Site
    • Kingwood, Texas, United States, 77339
      • Research Site
  • Utah
    • Salt Lake City, Utah, United States, 84108
      • Research Site
  • Vermont
    • Burlington, Vermont, United States, 05401
      • Research Site
• Vietnam
  • Hanoi, Vietnam, 100000
    • Research Site
  • Ho Chi Minh City, Vietnam, 700000
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 130 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Participant must be ≥ 40 years of age and capable of giving signed informed consent.
2. Documented diagnosis of COPD for at least one year prior to enrolment.
3. Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value.
4. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
5. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment.
6. Smoking history of ≥ 10 pack-years.
7. CAT total score ≥10, with each of the phlegm (sputum) and cough items with a score ≥ 2.

Exclusion Criteria:

1. Clinically important pulmonary disease other than COPD.
2. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.
3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.
5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization.
6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.
7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.
8. Significant COVID-19 illness within the 6 months prior to enrolment.
9. Unstable cardiovascular disorder.
10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.
11. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2.
12. History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C)
13. Evidence of active liver disease, including jaundice during screening.
14. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.
15. Participants who have evidence of active TB.
16. Participants that have previously received tozorakimab.
17. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
18. Active vaping of any products or using smoked marijuana within the 6 months prior to randomization and during the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tozorakimab Dose 1; Dosing subcutaneously tozorakimab Dose 1 and placebo	Drug: Tozorakimab; Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.; Drug: Tozorakimab; Administered subcutaneously tozorakimab Dose 2 through Week 52.
Experimental: Tozorakimab Dose 2; Dosing subcutaneously tozorakimab Dose 2	Drug: Tozorakimab; Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.; Drug: Tozorakimab; Administered subcutaneously tozorakimab Dose 2 through Week 52.
Placebo Comparator: Placebo; Dosing subcutaneously with equivalent volume to tozorakimab	Drug: Placebo; Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.	The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy [triple therapy, or dual therapy if triple is not considered appropriate]) and then assessed in the overall population of participants.	over 52 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annualized rate of moderate to severe COPD exacerbations in former or current smokers.	The annualized rate will be assessed in the overall population of participants including current and former smokers with symptomatic COPD and history of exacerbations, on optimised treatment with maintenance inhaled therapy.	over 52 weeks
Time to first moderate to severe COPD exacerbation in former smokers.	To explore the extent to which treatment with each dose of tozorakimab delays the time to first exacerbation compared with placebo in former smokers.	over 52 weeks
Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in former smokers.	Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers.	Week 52, or over 52 weeks
Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in the overall population of current and former smokers.	Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in the overall population of current and former smokers.	Week 52, or over 52 weeks
Percentage of responders achieving MCID in E-RS:COPD total score in former smokers.	Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in former smokers.	Week 52
Percentage of responders achieving MCID in E-RS:COPD total score in the overall population of current and former smokers.	Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in the overall population of current and former smokers.	Week 52
Mean change from baseline in E-RS:COPD total score in former smokers.	Difference in mean change in E-RS:COPD total score from baseline in former smokers.	over 52 weeks
Mean change from baseline in E-RS:COPD total score in the overall population of current and former smokers.	Difference in mean change in E-RS:COPD total score from baseline in the overall population of current and former smokers.	over 52 weeks
Percentage of responders achieving MCID in SGRQ total score in former smokers.	Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in former smokers.	Week 52
Percentage of responders achieving MCID in SGRQ total score in the overall population of current and former smokers.	Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in the overall population of current and former smokers.	Week 52
Mean change from baseline in SGRQ total score from in former smokers.	Difference in mean change from baseline in SGRQ total score in former smokers.	over 52 weeks
Mean change from baseline in SGRQ total score from in the overall population of current and former smokers	Difference in mean change from baseline in SGRQ total score in the overall population of current and former smokers.	over 52 weeks
Time to first severe COPD exacerbation in former smokers.	To evaluate hazard ratio of first severe COPD exacerbation in former smokers.	over 52 weeks
Annualized rate of severe COPD exacerbations in former smokers.	The rate ratio of severe COPD exacerbations will be assessed in former smokers.	over 52 weeks
Change from baseline in CAT total score.	Analyses of change from baseline in CAT total score in former smokers.	Week 52
Percentage of participants with a decrease in CAT total score in former smokers.	Proportion of participants achieving MCID in CAT total score, a decrease in CAT total score of ≥ 2 points from baseline in former smokers.	Week 52
Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.	Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.	over 52 weeks
Annualized rate of healthcare resource utilization in former smokers.	Annualized rate of healthcare resource utilization in former smokers.	over 52 weeks
The change from baseline in mean number of puffs per day in rescue use in former smokers.	Difference in mean number of puffs per day from baseline.	over 52 weeks
Trough serum concentrations of tozorakimab.	Pharmacokinetics: concentrations of tozorakimab in trough serum.	over 52 weeks
Presence of anti-drug antibodies.	Immunogenicity: presence of tozorakimab anti-drug antibodies in blood serum.	over 60 weeks

Collaborators and Investigators

• Sponsor: AstraZeneca

Study record dates

Study Major Dates

• Study Start (Actual): January 3, 2022
• Primary Completion (Actual): January 19, 2026
• Study Completion (Actual): March 11, 2026

Study Registration Dates

• First Submitted: December 9, 2021
• First Submitted That Met QC Criteria: December 9, 2021
• First Posted (Actual): December 22, 2021

Study Record Updates

• Last Update Posted (Actual): April 16, 2026
• Last Update Submitted That Met QC Criteria: April 15, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: COPD; exacerbations; Chronic Obstructive Pulmonary Disease; ICS; tozorakimab; LABA/LAMA
• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pathological Conditions, Signs and Symptoms; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: D9180C00003; 2021-003797-30 (EudraCT Number); 2023-503571-19-00 (Registry Identifier: CTIS)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No